deuterated sodium oxybate

JZP-386 is a deuterium-containing analog of sodium oxybate developed as a potential treatment for narcolepsy. It is a small-molecule drug designed to improve upon the pharmacokinetic and pharmacodynamic properties of sodium oxybate by incorporating deuterium atoms, which can slow metabolism and potentially enhance efficacy or safety. The mechanism of action is primarily as an agonist at the GABAB receptor, similar to its parent compound sodium oxybate; some sources also mention dopamine receptor agonism. JZP-386 was developed by Concert Pharmaceuticals in collaboration with Jazz Pharmaceuticals. Phase 1 clinical trials compared its effects to those of Xyrem (sodium oxybate) and placebo in healthy volunteers. Although favorable pharmacokinetic effects were observed due to deuteration (higher serum concentrations and increased pharmacodynamic effects), development has not advanced beyond early clinical studies due to insufficient differentiation from existing therapies[1][2][3][4][5][7][8].

Other names

deuterium-modified sodium oxybatedeuterium-containing analog of sodium oxybate